SANOFI news, videos and press releases - Page 3
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Press Release: Sanofi provides update on amcenestrant clinical development program
- Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
- Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
- Sanofi: Information concerning the total number of voting rights and shares – May 2022
- Availability of the Q2 2022 Memorandum for modelling purposes
- Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
- Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)
- Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
- Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
- Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
- Press Release: New nirsevimab data analyses reinforce efficacy against RSV
- Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence
- Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents
- Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
- Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
- Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
- Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
- Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
- Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
- Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
- Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
- Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma
- Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
- Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
- Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
- Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
- Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
- Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
- Sanofi: Information concerning the total number of voting rights and shares – December 2021
- Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines